<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098982</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16029</org_study_id>
    <secondary_id>EORTC-16029</secondary_id>
    <secondary_id>MILLENNIUM-EORTC-16029</secondary_id>
    <secondary_id>2004-001763-21</secondary_id>
    <nct_id>NCT00098982</nct_id>
  </id_info>
  <brief_title>Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some&#xD;
      of the enzymes needed for cell growth. It may also help the chemotherapy drugs work better by&#xD;
      making tumor cells more sensitive to the drugs. Giving bortezomib with fluorouracil,&#xD;
      leucovorin, and oxaliplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when&#xD;
      given with fluorouracil, leucovorin, and oxaliplatin in treating patients with advanced or&#xD;
      metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of bortezomib when&#xD;
           administered with fluorouracil, leucovorin calcium, and oxaliplatin in patients with&#xD;
           advanced or metastatic colorectal cancer.&#xD;
&#xD;
        -  Determine the recommended phase II dose of bortezomib in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine response in patients with measurable disease treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, multicenter, dose-escalation study of&#xD;
      bortezomib.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 8, and 15; oxaliplatin IV over 2&#xD;
      hours on days 1 and 15; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22&#xD;
      hours on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Additional patients receive treatment at the&#xD;
      MTD to a maximum of 12 patients at that dose level.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression or start of a new anticancer&#xD;
      treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: Not specified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by CTC v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as measured by RECIST every 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as measured by Kaplan Meier and RECIST every 8 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced or metastatic colorectal cancer&#xD;
&#xD;
          -  Amenable to first-line treatment with oxaliplatin, fluorouracil, and leucovorin&#xD;
             calcium for advanced or metastatic disease&#xD;
&#xD;
          -  No symptomatic or radiologic evidence of brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
          -  No clinically significant ECG changes&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No baseline neuropathy &gt; grade 1&#xD;
&#xD;
          -  No other prior or concurrent malignancy except cone-biopsied carcinoma of the cervix&#xD;
             or adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No unstable systemic disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  No hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  No prior chemotherapy for advanced or metastatic disease&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 14 days since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Caponigro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Nazionale per lo Studio e la Cura dei Tumori</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Caponigro F, Lacombe D, Twelves C, Bauer J, Govaerts AS, Marréaud S, Milano A, Anthoney A. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer. 2009 Jan;45(1):48-55. doi: 10.1016/j.ejca.2008.08.011. Epub 2008 Sep 20.</citation>
    <PMID>18809314</PMID>
  </results_reference>
  <results_reference>
    <citation>Lacombe DA, Caponigro F, Anthoney A, et al.: A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029. [Abstract] J Clin Oncol 25 (Suppl 18): A-4090, 2007.</citation>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

